Wednesday, 5 August 2026
Medicare reform for rural GPs, Stable high-dose vitamin B6 sales, OPTIRAY Imaging recall issued
- 01
Rural GPs call for Medicare reform to support long consultations
Rural GPs face increasing challenges from a Medicare system that favours short consultations, according to testimony at a recent Parliamentary Inquiry. Dr Rod Omond from the RACGP highlighted that the current funding model undervalues the long, complex consultations typical in rural practice, where patients often present with multiple conditions. He noted that while shorter consultations can generate higher income, they do not meet the comprehensive care needs of rural patients. The RACGP has called for structural reforms, including an independent Medicare pricing authority and increased rebates for longer consultations, to ensure sustainable healthcare access in rural communities.
via RACGP newsGP
- 02
High-dose vitamin B6 sales remain stable despite warnings
Sales of high-dose vitamin B6 supplements in Australia continue to be concerning, according to a University of Sydney study. Researchers found over 20 million products sold contained more than the daily dose of 5 mg, with more than three million exceeding 50 mg. Despite mandatory warnings and regulatory changes, purchasing patterns have not significantly changed, indicating ongoing public health risks. The study authors emphasised the need for improved risk communication and pharmacist oversight to address the widespread high-risk purchasing behaviours.
via RACGP newsGP
- 03
Liebel-Flarsheim recalls OPTIRAY Imaging Bulk Package due to safety concerns
Liebel-Flarsheim Company, LLC recalled one lot of OPTIRAY Imaging Bulk Package (IBP) 350, 500mL due to the presence of particulate matter. The product, which contains Ioversol Injection 74% (350 mg iodine/ml), is intended for intra-arterial or intra-venous use. The recall affects hospitals and imaging centres nationwide and in Mexico. This action underscores the importance of monitoring drug safety and regulatory compliance.
via FDA MedWatch
- 04
FDA Approves First Oral Carbapenem for Complicated UTIs
The US Food and Drug Administration (FDA) has approved the first oral carbapenem therapy for treating complicated urinary tract infections (UTIs). This approval marks a significant advancement in treatment options for this common condition.
via JAMA
- 05
Respiratory Biologics Approval Linked to Fewer Asthma Exacerbations
The approval of additional respiratory biologics for asthma has been associated with a significant decline in exacerbations, according to a study published in JAMA Network Open. This finding underscores the effectiveness of these treatments in clinical practice. The research highlights the impact of new biologic therapies on asthma management.
via JAMA
- 06
Nominations open for 2026 RACGP Faculty Council elections
Nominations have opened for the 2026 RACGP Faculty Council elections, inviting GPs across Australia to participate. Multiple positions are available across the college’s 11 Faculty Councils, with terms now extended to three years, except for specific conditions in Western Australia. Dr Rebekah Hoffman and Dr Toby Gardner highlighted the importance of these roles in advocating for general practice improvements, such as parental leave for registrars and enhanced access to ADHD diagnosis and meningococcal B vaccinations. Nominations close on 28 August, with voting scheduled from 7 September to 17 September.
via RACGP newsGP
MDDR is a news digest for medical professionals. It is not medical advice and should not be relied on for clinical decision-making.